NEWS
-
Hongmin Chen joins WARF Therapeutics
Chen to head biology for program aiming to produce preclinical candidates CONTACT: Jeanan Yasiri Moe Director of Strategic Communications [email protected] | (608) 960-9892 MADISON, Wis. – WARF Therapeutics, the multimillion-dollar…
-
WARF Therapeutics fall 2021 call for proposals
Program proposal deadline October 8 CONTACT: Jeanan Yasiri Moe Director of Strategic Communications [email protected] | (608) 960-9892 MADISON, Wis. – WARF Therapeutics collaborates with researchers to advance their work closer…
-
WARF Therapeutics spring 2021 call for proposals
Program proposal deadline April 5 CONTACT: Jeanan Yasiri Moe Director of Strategic Communications [email protected] | (608) 960-9892 MADISON, Wis. – WARF Therapeutics collaborates with researchers to advance their work closer…
-
WARF Therapeutics 2020 call for fall proposals
CONTACT: Jacqui Fuller, Strategic Communications and Marketing Manager [email protected] | 608.960.9881 Fall WARF Therapeutics (WT) Program Proposal Deadline: October 15 MADISON, Wis. – WARF Therapeutics encourages researchers working on a…
EVENTS
-
Wed 9November 9 @ 11:00 am - 12:00 pmTranslational Regulation of Breast Cancer Metastasis: Translation Initiation from the 3’ End
Translational Regulation of Breast Cancer Metastasis: Translation Initiation from the 3’ End
Robert Schneider, Ph.D., is the Albert Sabin Professor of Molecular Pathogenesis and co-director of the Breast Cancer Research Program at NYU School of Medicine. His lab performs basic, translational and…
-
Wed 12October 12 @ 11:00 am - 12:00 pmFrom Patient Mutations to Small Molecules: Lessons Learned from Protein Phosphatase 2A
From Patient Mutations to Small Molecules: Lessons Learned from Protein Phosphatase 2A
Dr. Goutham Narla earned his B.S. in biology and economics from Santa Clara University in California and his MD, Ph.D. and performed his residency at Mount Sinai School of Medicine…
For business questions, contact John Nagel or Rafael Diaz. If you are a PI interested in submitting your work to the program or talking through next steps, contact Jon Young. You do not need to have a patent; we are interested in talking with you about a new target early in your process.